Docetaxel And Paclitaxel Compared With Anthracycline-containing Chemotherapy In The Adjuvant Treatment For Women With 0～3 Stage Breast Cancer

ObjectiveTo estimate the clinical effectiveness docetaxel and paclitaxel compared with non-taxane, anthracycline-containing chemotherapy regimens, for the adjuvant treatment of women with 0-3 stage breast cancer.MethodsA systematic review of the adjuvant taxane versus anthracycline non-taxane chemotherapy for women with0-3 stage breast cancer was undertaken. A mathematical model was developed to synthesise the available data on disease-free survival and overall survival of patients receiving taxane-containing chemotherapy versus non-taxane-containing chemotherapy. All patients received at least 6 cycles chemo therapy.ResultsThe results show that the DFS and OS of the adjuvant taxane is 31 months and 32 months; while in non-taxane chemotherapy they are 33 months and 34 months.9 cases of recurrences were observed in taxane adjuvant group with the rate 8.1%,and 2 cases of death with the rate 1.8%;and in non-taxane chemotherapy group 21 cases (9.8%) relapsed, and 11casese (5%) died.ConclusionsAdjuvant chemotherapy with docetaxel and paclitaxel improve the DFS and OS in 3 stage patients and also in patients of lymphoid node stage 2.The analysis in the subgroup of triple-negtive breast cancer shows benefit from adjuvant chemotherapy with docetaxel and paclitaxel.